CD1D and neoplasm: Collectively, we have generated a first-in-class, off-the-shelf, humanized CD1d-Vδ2 bsTCE that selectively engages both type 1 NKT and Vγ9Vδ2-T cells to trigger a potent antitumor response to CD1d-expressing tumor cells.